Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Intermittent Claudication Market From 2025 To 2029?

Over the last few years, the size of the intermittent claudication market has been experiencing robust growth. Projections for the future indicate that the market will expand from $12.81 billion in 2024 to an estimated $13.51 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.5%. The growth observed in the historic period is thought to have been fueled by factors such as the escalating prevalence of peripheral artery disease, amplified awareness about vascular illnesses, a rising geriatric population, increased diagnosis rates, and a higher expenditure in the healthcare sector.

The market size for intermittent claudication is projected to experience significant growth in the forthcoming years, reaching$16.99 billion by 2029 at a compound annual growth rate (CAGR) of 5.9%. Several factors are anticipated to fuel this growth during the forecast period, including the escalating incidence of diabetes, increasing occurrences of obesity, a rise in cardiovascular diseases, an upward trend in alcohol and tobacco use, and augmented healthcare expenditure. In addition, the forecast period will also witness major trends such as progression in pad diagnostics, incorporation of wearable devices, introduction of personalized medicine, shift towards drug-eluting stents, and advancements in stem cell therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Intermittent Claudication Market?

The rise in instances of peripheral artery disease (PAD) is anticipated to drive the expansion of the intermittent claudication market. PAD, a circulatory issue characterized by constricted arteries leading to reduced blood flow to the limbs, results in pain, numbness, and other complications. This escalation in PAD cases largely results from factors such as an aging society, diabetes, smoking, hypertension, obesity, and inactive lifestyles. PAD induces intermittent claudication by curtailing blood flow to the leg muscles during physical activity, resulting in pain and muscle cramps due to insufficient oxygen. For example, in June 2023, statistics from the American Heart Association Journals, a U.S. based open-access scientific journal that is peer-reviewed, noted that PAD occurs in 7-12 million individuals in the U.S. and 200 million globally. Consequently, the upsurge in peripheral artery disease (PAD) cases is propelling the expansion of the intermittent claudication market.

Which Key Market Segments Comprise the Intermittent Claudication Market and Drive Its Revenue Growth?

The intermittent claudicationmarket covered in this report is segmented –

1) By Type: Medication Therapies; Revascularization

2) By Route Of Administration: Parenteral Route; Oral Route; Other Routes Of Administration

3) By Application: Hospitals; Clinics; Home Healthcare; Other Applications

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents; Vasodilators; Phosphodiesterase Inhibitors; Cilostazol; Pentoxifylline

2) By Revascularization: Angioplasty; Stenting; Bypass Surgery; Endarterectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

Which Areas Are Leading Regions in the Intermittent Claudication Market Expansion Across the Globe?

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theIntermittent Claudication Market Direction?

Leading businesses in the intermittent claudication market are prioritizing advanced therapeutic treatments, such as RIPK1 inhibitors, in their strategy to improve treatment effects for patients dealing with peripheral artery disease (PAD) experiencing intermittent claudication. The goal is to boost blood circulation, lessen inflammation, and halt disease progression. RIPK1 inhibitors are specialized drugs that hinder RIPK1 kinase activity, thereby minimizing inflammation and cellular death. For example, GenFleet, a biotech firm based in China, acquired a US Food and Drug Administration (FDA) approval for a Phase II clinical trial of GFH312, a novel therapy for peripheral artery disease (PAD) with intermittent claudication, in August 2022. This research, which is randomized, double-blinded, and placebo-controlled, will take place across 15 research facilities. GFH312 is a RIPK1 inhibitor that has displayed potential in preliminary studies by suppressing the inflammatory response in animal models.

View the full report here:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

How Is the Intermittent Claudication Market Conceptually Defined?

Intermittent claudication is a condition characterized by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is typically caused by peripheral artery disease (PAD), which results from narrowed or blocked arteries reducing blood flow to the muscles. The pain is often due to insufficient oxygen supply (ischemia) to the affected muscles.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model